Home » About Us » Clinical Trials » Ocriplasmin Research to Better Inform Treatment (ORBIT)
Ocriplasmin Research to Better Inform Treatment (ORBIT)
This trial has ended
Research Title: This is a multicenter, prospective, observational, Phase 4 study that will assess clinical outcomes and safety of JETREA® administered in a real-world setting for the treatment of symptomatic vitreomacular adhesion (VMA) by assessing anatomical and functional outcomes in 1500 patients recruited across approximately 120 USA retina sites.
Sponsor: ThromboGenics
Principal Investigator: Michael Jacobson, M.D.
Description: The sites will prospectively enroll consecutive patients eligible for participation in the study. Informed consent will be obtained prior to any data being collected. This study is observational; therefore, all treatment decisions and assessments are at the discretion of the patient’s treating physician and are not mandated by the study design or protocol. Patients will be enrolled at a routinely scheduled visit, on the day pf JETRA® administration after the JETREA® injection. No specific visits, examinations, laboratory tests or procedures are mandated as part of this study. There is no pre-set visit schedule, and the frequency and timing of actual patient visits is at the discretion of the treating physician following standard of care. All available and relevant data will be collected prospectively.
Start Date: April 2014
Recruitment: Completed
Project Personnel: Leslie Marcus, CCRC
Location(s): Tucker; 1462 Montreal Road West, Suite 412, Tucker, GA 30084
Northside; 1100 Johnson Ferry Rd. Bldg. 2, Suite 593, Atlanta, GA 30342
Marietta; 833 Campbell Hill Street, Suite 300, Marietta, GA 30060
Clinical Trial Team
Active Trials
- Amgen 20170542
- Apellis APL2-303 DERBY
- Gemini GEM-NH-001 Clarity 1
- Genentech GR40349 YOSEMITE
- Genentech GR40548 ARCHWAY
- Genentech GR40973 Gallego
- Gyroscope Therapeutics GTSCOPE
- Iveric Bio ISEE2008 GATHER2
- NGM Biopharmaceuticals NGM621-GA-201 CATALINA
- Novartis CRTH258A2303 TALON
- Novartis CRTH258B2305 Kingfisher
- Novartis CRTH258C2302 Raven
- Novo Nordisk NN9535-4352 FOCUS
- Regeneron VGFTe(HD)-DME-1934 PHOTON
- Roche GR40549 PORTAL
- Roche GR40550 PAGODA
- Roche GR40844 LUCERNE
- Roche GR41675 PAVILION
- Roche GR41987 RHONE-X
- SamChungDang SCD411-CP101
- Xbrane XBR1002 XPLORE
Past Trials
- AART C-02-60
- Acucela 4429-202 SEATTLE
- Aerpio AKB-9778-CI-5001 TIME-2b
- Allergan 150998-005 CEDAR
- Allergan 1771-201-008 MAPLE
- Allergan 190342-038 BEACON
- ALLERGAN 206207-012
- AREDS2
- AREDS2 ForeseeHome
- C-09-067 RACE
- DRCR.net Protocol N
- Gemini GEM-NH-002 Clarity 2
- Genentech GR39821
- Graybug GBV-102-002 Altissimo
- HORIZON FVF3426g
- KalVista KVD011-201
- LFG316A2203
- MARINA FVF2598g
- Novartis CSPP100A2244
- Ocriplasmin Research to Better Inform Treatment (ORBIT)
- OPH1002
- OPH1004
- Ophthotech OPH2003
- PDEX
- Regeneron R2176-3-AMD-1417 CAPELLA
- Regeneron R910-3-AMD-1517 ONYX
- Regeneron R910-3-DME-1518 RUBY
- Regeneron VGFTe-OD-1411 PANORAMA
- RIDE FVF4168g
- RISE FVF4170g
- Roche BP 30099 BOULEVARD
- Roche BP29647 AVENUE
- Roche GX29176 CHROMA
- Roche GX30191 OMASPECT
- SAILOR FVF3689g
- SCORE
- SCORE2
- Suprachoroidal Buckling for Retinal Detachment
- Taiwan Liposome Company (TLC) TLC399A2002
- Xcenda C-01-17 ForeseeHome